SCHEMBL14024980

SCHEMBL14024980

CC(C)CCCCNC(N)=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP7 Q9UHL4 2/20 0.40
EPHX1 P07099 2/20 0.40
KDM4E B2RXH2 1/20 0.39
MAPK1 P28482 1/20 0.39
HIF1A Q16665 1/20 0.39
ANPEP P15144 3/20 0.39
RNPEP Q9H4A4 2/20 0.39
DNPEP Q9ULA0 2/20 0.39
GNAI3 P08754 1/20 0.39
GNAO1 P09471 1/20 0.39
GNAI1 P63096 1/20 0.39
MMP8 P22894 1/20 0.39
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
PAOX Q6QHF9 2/20 0.38
LMNA P02545 1/20 0.37
KDM4C Q9H3R0 2/20 0.37
RRM1 P23921 1/20 0.37
KDM4A O75164 1/20 0.37
PHF8 Q9UPP1 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19468492 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19458777 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL8432422 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19468535 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19468450 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19468504 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19468498 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19458557 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19468489 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A
SCHEMBL19468522 0.98 EPHX1 (0.43) DPP7EPHX1KDM4EMAPK1HIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110437158-B Preparation and application of anthracene-based hydrogen bond molecule folding material 常州大学 2023-01-17 CN claimed
WO-2024043261-A1 AZO COMPOUND OR SALT THEREOF, AND POLARIZING FILM, POLARIZING PLATE AND LIQUID CRYSTAL DISPLAY DEVICE COMPRISING SAME 日本化薬株式会社 2024-02-29 WO disclosed
CN-114026199-B Polarized light emitting film, polarized light emitting panel and display device containing water-soluble coumarin compound or salt thereof 日本化药株式会社 2023-12-26 CN disclosed
US-20230019461-A1 POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2023-01-19 US disclosed
CN-110945083-B Styrene compound or salt thereof, polarizing film, polarizing plate and display device 日本化药株式会社 2022-07-01 CN disclosed
EP-3998502-A1 POLARIZED LIGHT-EMITTING FILM CONTAINING WATER-SOLUBLE COUMARIN COMPOUND OR SALT THEREOF, POLARIZED LIGHT-EMITTING PLATE, AND DISPLAY DEVICE Nippon Kayaku Kabushiki Kaisha (JP) 2022-05-18 EP disclosed
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME CDRD VENTURES INC. (CA) 2022-04-14 US disclosed
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same CDRD VENTURES INC. (CA) 2022-03-22 US disclosed
CN-114026199-A Polarizing luminescent film, polarizing luminescent sheet, and display device containing water-soluble coumarin compound or salt thereof 日本化药株式会社 2022-02-08 CN disclosed
US-10927155-B2 Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta George Mason Research Foundation, Inc. (US) 2021-02-23 US disclosed
US-9890178-B2 Azabenzimidazoles as respiratory syncytial virus antiviral agents JANSSEN SCIENCES IRELAND UC (IE) 2018-02-13 US disclosed
US-20170297355-A1 Heat-Sensitive Recording Material NIPPON KAYAKU KABUSHIKI KAISHA (JP) 2017-10-19 US disclosed
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME POSTECH ACADEMY-INDUSTRY FOUNDATION (KR) 2017-07-20 US disclosed
US-20160237096-A1 AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS JANSSEN SCIENCES IRELAND UC (IE) 2016-08-18 US disclosed
US-9321767-B2 Azabenzimidazoles as respiratory syncytial virus antiviral agents JANSSEN SCIENCES IRELAND UC (IE) 2016-04-26 US disclosed
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS ALIOS BIOPHARMA, INC. 2016-02-18 US disclosed
US-20150073012-A1 AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS JANSSEN SCIENCES IRELAND UC (IE) 2015-03-12 US disclosed
US-8927720-B2 Azabenzimidazoles as respiratory syncytial virus antiviral agents JANSSEN R&D IRELAND (IE) 2015-01-06 US disclosed
US-20130261151-A1 AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS JANSSEN R & D IRELAND (IE) 2013-10-03 US disclosed
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea METASTATIX, INC. 2008-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237096-A1 AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS AZI2, ZC3HAV1, ZC3HAV1L DPP7 416/4885EPHX1 3981/4885KDM4E 1223/4885
US-10927155-B2 Dual inhibitory action peptidomimetic inhibitor for IL-33 and IL-1beta IL33, IL1R1, IL1RN DPP7 1837/4885EPHX1 1978/4885KDM4E 4645/4885
US-20170204086-A1 ALPHA-HELIX ANALOG HAVING TRIAZINE-PIPERAZINE BACKBONE AND METHOD FOR PREPARING SAME HSPH1, HBZ, PITHD1 DPP7 1012/4885EPHX1 2442/4885KDM4E 4730/4885
US-20080261978-A1 treating or preventing HIV infections, and in treating proliferative disorders such as inhibiting the metastasis of various cancers; 1-(4-((pyridin-2-ylmethylamino)methyl)benzyl)-3-phenylurea MKI67, CCNI, CDKN1A DPP7 2334/4885EPHX1 971/4885KDM4E 532/4885
US-20150073012-A1 AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS ZC3HAV1, AZI2, ZC3HAV1L DPP7 329/4885EPHX1 4045/4885KDM4E 1258/4885
US-20170297355-A1 Heat-Sensitive Recording Material SCN1A, SCN3A, KCNN3 DPP7 3825/4885EPHX1 1015/4885KDM4E 3036/4885
US-11279732-B2 Somatostatin receptor antagonist compounds and methods of using the same GPR119, SSTR5, SSTR2 DPP7 171/4885EPHX1 4483/4885KDM4E 4118/4885
US-20160045528-A1 COMBINATION THERAPY FOR TREATING A PARAMYXOVIRUS MAVS, EIF2AK2, SARS1 DPP7 581/4885EPHX1 2989/4885KDM4E 4080/4885
US-20220112242-A1 SOMATOSTATIN RECEPTOR ANTAGONIST COMPOUNDS AND METHODS OF USING THE SAME GPR119, SSTR5, SSTR2 DPP7 170/4885EPHX1 4454/4885KDM4E 4069/4885
US-20130261151-A1 AZABENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS ZC3HAV1, AZI2, ZC3HAV1L DPP7 329/4885EPHX1 4045/4885KDM4E 1258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.